Log in

NASDAQ:ARWR - Arrowhead Pharmaceuticals Stock Price, Forecast & News

$28.12
-2.47 (-8.07 %)
(As of 03/29/2020 04:44 AM ET)
Today's Range
$27.95
Now: $28.12
$30.15
50-Day Range
$20.56
MA: $34.06
$42.85
52-Week Range
$17.30
Now: $28.12
$73.72
Volume1.27 million shs
Average Volume2.11 million shs
Market Capitalization$2.86 billion
P/E Ratio53.06
Dividend YieldN/A
Beta1.98
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma. It is also involved in the development of ARO-HBV, a third-generation subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; AMG 890 to reduce production of apolipoprotein A; and ARO-AMG1 for treating undisclosed genetically-validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreement with Amgen, Inc.; and Janssen Pharmaceuticals, Inc. to develop RNAi therapeutics. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Read More
Arrowhead Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ARWR
CUSIPN/A
Phone626-304-3400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$168.80 million
Cash Flow$0.71 per share
Book Value$2.57 per share

Profitability

Net Income$67.97 million

Miscellaneous

Employees116
Market Cap$2.86 billion
Next Earnings Date5/13/2020 (Estimated)
OptionableOptionable

Receive ARWR News and Ratings via Email

Sign-up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter.


Arrowhead Pharmaceuticals (NASDAQ:ARWR) Frequently Asked Questions

How has Arrowhead Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Arrowhead Pharmaceuticals' stock was trading at $28.56 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ARWR shares have decreased by 1.5% and is now trading at $28.12. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Arrowhead Pharmaceuticals?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Arrowhead Pharmaceuticals.

When is Arrowhead Pharmaceuticals' next earnings date?

Arrowhead Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for Arrowhead Pharmaceuticals.

How were Arrowhead Pharmaceuticals' earnings last quarter?

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) issued its quarterly earnings data on Wednesday, February, 5th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.04 by $0.07. The biotechnology company had revenue of $29.46 million for the quarter, compared to analysts' expectations of $36.63 million. Arrowhead Pharmaceuticals had a return on equity of 18.21% and a net margin of 32.56%. View Arrowhead Pharmaceuticals' earnings history.

What price target have analysts set for ARWR?

9 analysts have issued twelve-month target prices for Arrowhead Pharmaceuticals' stock. Their forecasts range from $29.00 to $81.00. On average, they expect Arrowhead Pharmaceuticals' stock price to reach $62.13 in the next year. This suggests a possible upside of 120.9% from the stock's current price. View analysts' price targets for Arrowhead Pharmaceuticals.

Has Arrowhead Pharmaceuticals been receiving favorable news coverage?

News stories about ARWR stock have trended somewhat positive this week, according to InfoTrie. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Arrowhead Pharmaceuticals earned a daily sentiment score of 1.2 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutArrowhead Pharmaceuticals.

Are investors shorting Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals saw a decrease in short interest in March. As of March 13th, there was short interest totaling 8,270,900 shares, a decrease of 5.2% from the February 27th total of 8,720,000 shares. Based on an average daily trading volume, of 1,587,800 shares, the days-to-cover ratio is currently 5.2 days. Approximately 8.9% of the company's stock are sold short. View Arrowhead Pharmaceuticals' Current Options Chain.

Who are some of Arrowhead Pharmaceuticals' key competitors?

What other stocks do shareholders of Arrowhead Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), AbbVie (ABBV), Advanced Micro Devices (AMD), Sarepta Therapeutics (SRPT), Bank of America (BAC), salesforce.com (CRM) and Bristol-Myers Squibb (BMY).

Who are Arrowhead Pharmaceuticals' key executives?

Arrowhead Pharmaceuticals' management team includes the following people:
  • Dr. Christopher R. Anzalone, CEO, Pres & Director (Age 50)
  • Mr. Kenneth A. Myszkowski, Chief Financial Officer (Age 53)
  • Dr. Bruce D. Given, Chief Operating Officer (Age 65)
  • Mr. Patrick O'Brien, Gen. Counsel (Age 55)
  • Dr. Mark M. Davis, Founder and Founder & Director of Insert Therapeutics Inc & Calando

What is Arrowhead Pharmaceuticals' stock symbol?

Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."

Who are Arrowhead Pharmaceuticals' major shareholders?

Arrowhead Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include State Street Corp (4.06%), FMR LLC (1.85%), Geode Capital Management LLC (1.41%), Fiera Capital Corp (1.34%), Bank of New York Mellon Corp (1.05%) and Norges Bank (1.03%). Company insiders that own Arrowhead Pharmaceuticals stock include Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Kenneth Allen Myszkowski, Mauro Ferrari, Michael S Perry, Patrick O'brien, Peter Brian Leone, William D Waddill and Zhen Li. View institutional ownership trends for Arrowhead Pharmaceuticals.

Which major investors are selling Arrowhead Pharmaceuticals stock?

ARWR stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Farallon Capital Management LLC, Candriam Luxembourg S.C.A., Principal Financial Group Inc., Rafferty Asset Management LLC, Goldman Sachs Group Inc., Oak Ridge Investments LLC, and Fiera Capital Corp. Company insiders that have sold Arrowhead Pharmaceuticals company stock in the last year include Bruce D Given, Christopher Richard Anzalone, Kenneth Allen Myszkowski, Mauro Ferrari, Michael S Perry, and Patrick O'brien. View insider buying and selling activity for Arrowhead Pharmaceuticals.

Which major investors are buying Arrowhead Pharmaceuticals stock?

ARWR stock was bought by a variety of institutional investors in the last quarter, including Norges Bank, Eagle Asset Management Inc., FMR LLC, Credit Suisse AG, American International Group Inc., Mutual of America Capital Management LLC, Retirement Systems of Alabama, and Geode Capital Management LLC. View insider buying and selling activity for Arrowhead Pharmaceuticals.

How do I buy shares of Arrowhead Pharmaceuticals?

Shares of ARWR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Arrowhead Pharmaceuticals' stock price today?

One share of ARWR stock can currently be purchased for approximately $28.12.

How big of a company is Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals has a market capitalization of $2.86 billion and generates $168.80 million in revenue each year. The biotechnology company earns $67.97 million in net income (profit) each year or $0.69 on an earnings per share basis. Arrowhead Pharmaceuticals employs 116 workers across the globe. View additional information about Arrowhead Pharmaceuticals.

What is Arrowhead Pharmaceuticals' official website?

The official website for Arrowhead Pharmaceuticals is http://www.arrowheadpharma.com/.

How can I contact Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals' mailing address is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. The biotechnology company can be reached via phone at 626-304-3400 or via email at [email protected]


MarketBeat Community Rating for Arrowhead Pharmaceuticals (NASDAQ ARWR)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  456 (Vote Outperform)
Underperform Votes:  444 (Vote Underperform)
Total Votes:  900
MarketBeat's community ratings are surveys of what our community members think about Arrowhead Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARWR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARWR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel